EZH2 and diffuse large B-cell lymphoma: Thus, we reanalyzed the primary DLBCL data with CIBERSORTx, and in a cohort that excluded tumors with mutations in other genes known to deregulate antigen presentation (CIITA, B2M, CREBBP, EP300, and EZH2), we detected an increase in Tregs (P = 0.05) in IRF8-mutant DLBCLs (Fig. 7B and fig.